BridgeBio Pharma, Inc.
Price Action
Technical Summary
CONSOLIDATINGBridgeBio Pharma, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 53), indicating performance broadly in line with the market. Earnings growth of 5% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $67.68 | +6.40% | ABOVE |
| 50 SMA | $68.82 | +4.64% | ABOVE |
| 100 SMA | $69.93 | +2.97% | ABOVE |
| 150 SMA | $71.66 | +0.49% | ABOVE |
| 200 SMA | $68.05 | +5.81% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BBIO in an uptrend right now?
BBIO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BBIO overbought or oversold?
BBIO's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is BBIO outperforming the market?
BBIO has a Relative Strength (RS) Rating of 53 out of 99. BBIO is performing about average compared to the market.
Where is BBIO in its 52-week range?
BBIO is trading at $72.01, which is 85% of its 52-week high ($84.94) and 70% above its 52-week low ($41.80).
How volatile is BBIO?
BBIO has a Beta of 1.07 and 52-week volatility of 46%. It's more volatile than the S&P 500 - expect bigger swings.